Respiratory Disease News and Research

RSS

Paracetamol linked to childhood asthma: study

New Zealand researchers have found that young kids given fever medicine Paracetamol are twice as likely to develop asthma. The study is an observational one by the University of Otago Wellington researchers where the team looked at Paracetamol use in 505 infants and 914 five and six-year-olds.

28 Nov 2010

Pollen burst leads to 10 year spike in asthma cases

Melbourne hospitals are flooded with patients with respiratory problems in a phenomenon experts have described as “thunderstorm asthma”.

25 Nov 2010

Asbestos awareness important to prevent related cancer: Experts

Experts from Perth speculate Western Australia is yet to see the peak of asbestos-induced cancer, with renovators still failing to take proper precautions. According to director of the National Centre for Asbestos Related Diseases, Bruce Robinson, the next and third wave of mesothelioma patients would come out of those putting themselves and others at risk while taking on DIY home renovation projects.

22 Nov 2010

FDA grants orphan drug designation to Discovery's KL4 surfactant for CF treatment

Discovery Laboratories, Inc. today announced that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan drug designation to Discovery's KL4 surfactant for the treatment of cystic fibrosis (CF).

1 Nov 2010

New shuttlte program helps probe spaceflight-induced immune-system impairment

When the space shuttle Discovery lifts off on its final flight Nov. 2, its six astronauts will be joined by 16 rodent passengers on a historic mission of their own. Riding in special self-contained modules that automatically supply them with food and water, the mice will be part of a long-term NASA effort aimed at understanding why spaceflight makes humans more vulnerable to infection by viruses and bacteria.

30 Oct 2010

CSL Behring creates Interlaken Leadership Awards to support innovative immunoglobulin research

To demonstrate its continued commitment to innovative immunoglobulin (Ig) research, CSL Behring announced today it has created the Interlaken Leadership Awards. This global awards program will provide monetary grants to advance medical research and knowledge about the potential role of immunoglobulin therapy in the treatment of neurologic disorders.

29 Oct 2010

New eight-month pilot program to advance standards of care for people with schizophrenia

The National Council for Community Behavioral Healthcare (National Council) today announced a new eight-month pilot program designed to advance standards of care for people living with schizophrenia. This initiative at 10 community behavioral health organizations nationwide is designed to improve the daily functioning of people with schizophrenia and raise expectations for what is achievable.

29 Oct 2010

Scientists identify potential new treatment for Nipah and Hendra viruses

Scientists at Weill Cornell Medical College have identified a potential new treatment for the Nipah and Hendra viruses, two lethal and emerging viruses for which there is currently no treatment or vaccine available. The approach could also lead to new therapies for measles, mumps and the flu. The new research appears in today's edition of the prestigious journal Public Library of Science (PLoS) Pathogens.

29 Oct 2010

Aradigm reports positive data from DRCFI, ARD-3150 Phase 2b bronchiectasis study

Aradigm Corporation today announced positive top line data from its recently concluded 6-month Phase 2b study (ORBIT-2) with Aradigm's once-daily dual release ciprofloxacin for inhalation (DRCFI, ARD-3150) in patients with non-cystic fibrosis bronchiectasis.

20 Oct 2010

Vivaglobin therapy effective for patients with primary immunodeficiency

Vivaglobin (subcutaneous immunoglobulin [IgG]) (SCIg) is an effective and safe initial therapy for treatment-naive patients with primary immunodeficiency (PI) and may offer an attractive alternative to intravenous IgG (IVIg) therapy in the newly diagnosed, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies.

7 Oct 2010

Privigen IVIg therapy effective for primary, secondary immunodeficiencies: Study

Privigen, the first and only 10% liquid intravenous immunoglobulin (IVIg) therapy stabilized with proline, is effective and well tolerated in patients with several primary and secondary immunodeficiencies, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies. Results also demonstrate that Privigen offers significant protection against infection.

7 Oct 2010

Hizentra therapy effective for primary immunodeficiency patients

Hizentra (IgPro20) provides primary immunodeficiency (PI) patients with a safe and effective alternative to other immunoglobulin therapies when given in equivalent doses, according to Phase III pivotal trial data presented today at the XIVth Meeting of the European Society for Immunodeficiencies (ESID).

7 Oct 2010

Scientist discovers novel pathogen from Mycobacterium tuberculosis complex

Kathleen Alexander, associate professor of wildlife in Virginia Tech's College of Natural Resources and Environment, has discovered a novel tuberculosis (TB) species in the Mycobacterium tuberculosis complex, a group of pathogens that have adapted by using mammals as hosts. It has been nearly two decades since a new organism was identified in this group; the majority were discovered in the early and mid 20th century.

3 Oct 2010

Report finds foreclosures harm people's health in California; Wash. small business health insurance program starts to sign up members

"A report released Wednesday found foreclosures have not only economic consequences, but create health problems for the people and families involved -- and those effects can ripple throughout a community. In a survey of nearly 400 residents in two Oakland neighborhoods particularly hard hit by the foreclosure crisis, the Alameda County Public Health Department and Causa Justa/Just Cause, a housing rights group, teamed up to look at how people undergoing foreclosure experience higher levels of stress and increased medical" (Colliver, 9/2).

3 Sep 2010

Ten million face hunger in Central Africa; Niger flooding exacerbates food shortage, leaves 200,000 homeless

Flash floods have "worsened an already chronic humanitarian crisis caused by drought" in central Africa where aid agencies have warned that "10 million people are already facing severe food shortages, particularly in the landlocked countries of Chad and Niger, after a drought led to the failure of last year's crops," the Independent reports.

31 Aug 2010

CPF continues partnership with American Thoracic Society to fund Pulmonary Fibrosis research

The Coalition for Pulmonary Fibrosis (CPF) and the American Thoracic Society (ATS), the world's leading professional organization for pulmonary, critical care and sleep physicians, today announced that the CPF will again partner with the ATS to continue to fund Pulmonary Fibrosis (PF) research.

24 Aug 2010

FDA approves CSL Behring's sBLA to extend shelf life of Hizentra from 18 to 24 months

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to extend the shelf life of Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, from 18 months to 24 months. Hizentra, the first and only 20 percent subcutaneous immunoglobulin (SCIg) approved in the U.S. by the FDA, is also the first and only SCIg in the U.S. that may be stored at room temperature.

19 Aug 2010

FDA approves N30 Pharma's NDA for N6022 GSNOR

N30 Pharmaceuticals, LLC today announced the approval of its Investigational New Drug Application for N6022 by the U.S. Food and Drug Administration. N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR), has the potential to be an important new treatment for acute exacerbations of asthma, chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD).

3 Aug 2010

NSW school heaters to be replaced

Unflued gas heaters in public schools posed a risk of respiratory ailments to students, a report found. Education Minister Verity Firth announced yesterday that the NSW government will replace these heaters. The government funded study to look at the effects of these low-emission unflued gas heaters in NSW public schools found “no measurable adverse changes in lung function” but said it was important to seek “alternative, effective and efficient sources of domestic and public space heating that does not have adverse effects”.

27 Jul 2010

New data on health insurance to be included in AHRQ's 2009 State Snapshots

The Agency for Healthcare Research and Quality's annual release of state-by-state quality data has been expanded to include new data on health insurance, including data on health care quality categorized by source of payment, including private insurance, Medicare, Medicaid and those without insurance.

23 Jul 2010

Respiratory Disease News and Research

Paracetamol linked to childhood asthma: study

Pollen burst leads to 10 year spike in asthma cases

Asbestos awareness important to prevent related cancer: Experts

FDA grants orphan drug designation to Discovery's KL4 surfactant for CF treatment

New shuttlte program helps probe spaceflight-induced immune-system impairment

CSL Behring creates Interlaken Leadership Awards to support innovative immunoglobulin research

New eight-month pilot program to advance standards of care for people with schizophrenia

Scientists identify potential new treatment for Nipah and Hendra viruses

Aradigm reports positive data from DRCFI, ARD-3150 Phase 2b bronchiectasis study

Vivaglobin therapy effective for patients with primary immunodeficiency

Privigen IVIg therapy effective for primary, secondary immunodeficiencies: Study

Hizentra therapy effective for primary immunodeficiency patients

Scientist discovers novel pathogen from Mycobacterium tuberculosis complex

Report finds foreclosures harm people's health in California; Wash. small business health insurance program starts to sign up members

Ten million face hunger in Central Africa; Niger flooding exacerbates food shortage, leaves 200,000 homeless

CPF continues partnership with American Thoracic Society to fund Pulmonary Fibrosis research

FDA approves CSL Behring's sBLA to extend shelf life of Hizentra from 18 to 24 months

FDA approves N30 Pharma's NDA for N6022 GSNOR

NSW school heaters to be replaced

New data on health insurance to be included in AHRQ's 2009 State Snapshots

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News